Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Appl Toxicol. 2016 May 17;37(2):181–191. doi: 10.1002/jat.3339

Figure 2.

Figure 2

Effects of 24 h exposure to 0.05 and 0.1 μM DBT on IL-1β secretion from monocyte-depleted PBMCs treated with selective pathway component inhibitors in individual donors. A) IL-1β Cleavage Inhibitor (Caspase-1 Inhibitor II) (donor F245). B) NFκB Inhibitor (BAY 11-7085) (donor F244). C) MEK 1/2 (p44/42) Inhibitor (U0126) (donor F240). D) p38 Inhibitor (SB202190) (donor F247).